Drugs / FF-10502-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02661542 | Jan 2016 → Nov 2020 | cancer, lymphoma | Fujifilm Pharmaceuticals U.S.A., Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FF-10502-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02661542 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT02661542 ↗ |